Are Nath Bio-Genes (India) Ltd latest results good or bad?

1 hour ago
share
Share Via
Nath Bio-Genes (India) Ltd's latest results show strong revenue growth of 78.90% to ₹65.96 crores, but net profit fell 39.62% to ₹1.60 crores, indicating significant profitability issues and operational challenges. The company's declining margins and rising interest costs raise concerns about its financial health and sustainability.
Nath Bio-Genes (India) Ltd's latest financial results for Q3 FY26 present a complex picture characterized by significant revenue growth juxtaposed with deteriorating profitability metrics. The company reported net sales of ₹65.96 crores, reflecting a substantial year-on-year growth of 78.90%. This growth is largely attributed to the seasonal demand typical in the agricultural sector, particularly during the peak agricultural season. However, despite this topline growth, the net profit fell to ₹1.60 crores, marking a decline of 39.62% compared to the previous year.
The operational challenges are evident in the company's operating margin, which collapsed to 5.43% from 21.81% a year earlier, indicating severe margin compression. This decline in profitability is compounded by rising interest costs, which reached ₹4.54 crores, consuming a significant portion of the operating profit. The interest burden has raised concerns about the company's ability to manage its financial obligations effectively, particularly during leaner quarters. Furthermore, the nine-month performance for FY26 reveals that a substantial portion of the profit was generated in the first quarter, highlighting the company's reliance on seasonal sales and raising questions about the sustainability of its earnings. The company's return on equity (ROE) and return on capital employed (ROCE) remain low, suggesting inefficiencies in capital allocation and underperformance relative to industry standards. In light of these results, Nath Bio-Genes experienced an adjustment in its evaluation, reflecting the market's concerns regarding its financial health and operational challenges. The company's stock has underperformed relative to its sector peers, indicating a lack of investor confidence amidst these fundamental weaknesses. Overall, the financial data suggests that while revenue growth is present, it is overshadowed by significant profitability issues and operational stress, necessitating urgent management actions to address these challenges.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News